Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Sabinsa Corporation Receives GRAS Notification for its Branded Ingredient Cococin(TM)
Sabinsa Corporation has announced that it has received Generally Recognized As Safe (GRAS) status for its branded ingredient Cococin(TM), coconut water solids, after an intensive review of safety and toxicology data by an independent panel of respected scientists assembled by Soni & Associates, Inc.
- Sabinsa Corporation Receives GRAS Notification for its Branded Ingredient Cococin(TM)
Sabinsa Corporation has announced that it has received Generally Recognized As Safe (GRAS) status for its branded ingredient Cococin(TM), coconut water solids, after an intensive review of safety and toxicology data by an independent panel of respected scientists assembled by Soni & Associates, Inc.
- Sabinsa Corporation Receives GRAS Notification for its Branded Ingredient Cococin(TM)
Sabinsa Corporation has announced that it has received Generally Recognized As Safe (GRAS) status for its branded ingredient Cococin(TM), coconut water solids, after an intensive review of safety and toxicology data by an independent panel of respected scientists assembled by Soni & Associates, Inc.
- Sabinsa Corporation Receives GRAS Notification for its Branded Ingredient Cococin(TM)
Sabinsa Corporation has announced that it has received Generally Recognized As Safe (GRAS) status for its branded ingredient Cococin(TM), coconut water solids, after an intensive review of safety and toxicology data by an independent panel of respected scientists assembled by Soni & Associates, Inc.
- HHS Announces New International Programs to Enhance Drug and Food Safety
U.S. Health and Human Services (HHS) Secretary Mike Leavitt has announced two groundbreaking programs designed to enhance the safety of food and medical products exported to the United States- Joint Inspections with European Union and Australian Regulators and a Third-Party Certification Program.
- HHS Announces New International Programs to Enhance Drug and Food Safety
U.S. Health and Human Services (HHS) Secretary Mike Leavitt has announced two groundbreaking programs designed to enhance the safety of food and medical products exported to the United States- Joint Inspections with European Union and Australian Regulators and a Third-Party Certification Program.
- Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods
The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams.
- Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods
The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams.
- Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods
The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams.
- Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods
The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams.
- IADSA workshop keeps the focus on Latin America
Regulators from Argentina, Chile and Brazil have taken part in workshop in Argentina organised by the International Alliance of Dietary/Food Supplement Associations (IADSA) to address global, regional and national regulatory trends. Held last month in Buenos Aires, the workshop gave the representatives the opportunity to learn about other regulatory systems in the area of dietary supplements.
- IADSA workshop keeps the focus on Latin America
Regulators from Argentina, Chile and Brazil have taken part in workshop in Argentina organised by the International Alliance of Dietary/Food Supplement Associations (IADSA) to address global, regional and national regulatory trends. Held last month in Buenos Aires, the workshop gave the representatives the opportunity to learn about other regulatory systems in the area of dietary supplements.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Defendants in International Spam Operation Settle FTC Charges; New Canadian Defendants Identified
Defendants in an operation that sold bogus weight loss supplements through illegal spam e-mail have settled Federal Trade Commission charges that their operation violated federal laws. The settlement bars them from making false or unsubstantiated claims about health benefits of any food, drug, or dietary supplements; bars violations of the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, known as the CAN-SPAM Act; and requires them to give up $29,000 in ill-gotten gains.
- Defendants in International Spam Operation Settle FTC Charges; New Canadian Defendants Identified
Defendants in an operation that sold bogus weight loss supplements through illegal spam e-mail have settled Federal Trade Commission charges that their operation violated federal laws. The settlement bars them from making false or unsubstantiated claims about health benefits of any food, drug, or dietary supplements; bars violations of the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, known as the CAN-SPAM Act; and requires them to give up $29,000 in ill-gotten gains.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs
Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud.
- Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs
Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States.
However, the European Federation of Associations of Health Product Manufacturers (EHPM) said that it still held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
The novel food catalogue is the result of the ongoing discussions in the Novel Food Working Group of Member State experts and Commission officials. It contains information on the EU history of certain ingredients used in foods, including food supplements, but is not considered as an exhaustive list of novel foods. The catalogue – which had previously circulated as an informal document internally within the European Commission – contains a list of ingredients which have been discussed between Member States and the Commission in relation to their status within the scope of the Novel Food Regulation.
The Commission’s website has made it clear that the catalogue should not be not taken at face value by either authorities or stakeholders for the determination of the classification of products, stating: “The information provided by this document should be used without prejudice to decisions that might be taken by Member States or the Commission on the basis of new or more completed information.”
However, EHPM said that it fears Member States may still take it up as a legal document.The organisation also questioned the catalogue’s existence, saying that the process for its establishment has not provided a transparent dialogue with interested stakeholders.
Lorene Courrege, EHPM Director of Regulatory Affairs, said: “We are reassured with the provisions published on the Commission’s website regarding the novel food catalogue, because it states that this only a orientation document and is considered as a living database subject to changes. However we still are concerned that some national authorities may use the document as a legal reference, meaning that once an ingredient appears on the list that may immediately trigger its consideration as a novel food ingredient. This will have a commercial impact on products without giving the industry the opportunity to provide information to prove the ingredient should not have novel food status.”
ENDS
The European Federation of Associations of Health Product Manufacturers (EHPM) was created in 1975 and represents 2000 specialist health product manufacturers across Europe.
EHPM works to provide consumers with safe, science-based, high quality products as well as accurate and helpful information about their nutritional value and use.
To contact EHPM email secretariat@ehpm.be, tel + (32) 2 209 11 45, or visit www.ehpm.org |